My current research involves the application of nutrigenetics and nutrigenomics to flaxseed derived nutraceuticals' prevention and post-onset management of type 2 diabetes in humans with a view to the reduction of polypharmacy. I, in collaboration with others, am also attempting to find the molecular cause(s) of type 2 diabetes. Other collaborative efforts include utilising an ammonia lyase to synthesise a potential pharmaceutical and optimising conditions to maximise the yield of product, researching why Cape Bretoners suffer from among the highest incidence and prevalence of type 2 diabetes in Canada and how to reduce such, the impact of dietary pulses on plasma lipid/lipoprotein/apolipoprotein B management, glycaemic index impact on low density lipoprotein oxidation management via improvements in plasma antioxidant management in overweight and obese persons as well as in gestational diabetes patients, and improvements in the clinical management of type 2 diabetes from both pre- and post-onset perspectives in first nations populations across Canada.
